WO2020210320A8 - Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones - Google Patents

Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones Download PDF

Info

Publication number
WO2020210320A8
WO2020210320A8 PCT/US2020/027218 US2020027218W WO2020210320A8 WO 2020210320 A8 WO2020210320 A8 WO 2020210320A8 US 2020027218 W US2020027218 W US 2020027218W WO 2020210320 A8 WO2020210320 A8 WO 2020210320A8
Authority
WO
WIPO (PCT)
Prior art keywords
pyrazolo
pyrimidin
dihydro
ones
substituted
Prior art date
Application number
PCT/US2020/027218
Other languages
French (fr)
Other versions
WO2020210320A1 (en
Inventor
Peter Qinhua HUANG
Kevin Duane BUNKER
Brant Clayton Boren
Aditya Krishnan UNNI
Sunny Abraham
Original Assignee
Recurium Ip Holdings, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recurium Ip Holdings, Llc filed Critical Recurium Ip Holdings, Llc
Publication of WO2020210320A1 publication Critical patent/WO2020210320A1/en
Publication of WO2020210320A8 publication Critical patent/WO2020210320A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.
PCT/US2020/027218 2019-04-11 2020-04-08 Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones WO2020210320A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962832529P 2019-04-11 2019-04-11
US62/832,529 2019-04-11

Publications (2)

Publication Number Publication Date
WO2020210320A1 WO2020210320A1 (en) 2020-10-15
WO2020210320A8 true WO2020210320A8 (en) 2020-11-12

Family

ID=72750610

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/027218 WO2020210320A1 (en) 2019-04-11 2020-04-08 Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones

Country Status (1)

Country Link
WO (1) WO2020210320A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL276802B2 (en) 2018-03-09 2023-09-01 Recurium Ip Holdings Llc Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
JP2024517085A (en) * 2021-04-12 2024-04-19 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー WEE1 Compounds for Treating Uterine Serous Carcinoma - Patent application
WO2023016417A1 (en) * 2021-08-11 2023-02-16 微境生物医药科技(上海)有限公司 1,2-dihydro-3h-pyrazol[3,4-d]pyrimidin-3-one compound as wee-1 inhibitor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20080695A1 (en) * 2006-04-27 2008-06-28 Banyu Pharma Co Ltd DIHYDROPIRAZOLOPYRIMIDINONE DERIVATIVES AS KINASE WEEL INHIBITORS
JPWO2009054332A1 (en) * 2007-10-23 2011-03-03 萬有製薬株式会社 Pyridone-substituted dihydropyrazolopyrimidinone derivatives
TW201910335A (en) * 2017-08-01 2019-03-16 美商薩諾皇家麥爾斯通有限責任公司 1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one analog
US11299493B2 (en) * 2017-10-09 2022-04-12 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
IL276802B2 (en) * 2018-03-09 2023-09-01 Recurium Ip Holdings Llc Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones

Also Published As

Publication number Publication date
WO2020210320A1 (en) 2020-10-15

Similar Documents

Publication Publication Date Title
WO2019173082A8 (en) Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
MX2020001235A (en) 1, 2 - dihydro- 3h- pyrazolo [3, 4 - d] pyrimidin -3 - one analogs.
WO2019139899A8 (en) Benzamide compounds
MX2022008066A (en) Substituted tricyclic compounds.
MX2022006475A (en) Substituted tricyclic compounds.
WO2020210320A8 (en) Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
GEP20237561B (en) Protein tyrosine phosphatase inhibitors
WO2020257549A3 (en) Compounds for treatment of pd-l1 diseases
TW200745066A (en) Novel PTP1B inhibitors
WO2005105753A8 (en) Naphthalimide derivatives, methods for their production and pharmaceutical compositions therefrom
MX2021012105A (en) Pyrrole compounds.
MX2021012423A (en) Methods and compositions for targeted protein degradation.
MX2022015703A (en) 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders.
CR20210513A (en) Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease
MX2020008746A (en) 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer.
MX2021007247A (en) Rapamycin derivatives.
MX2022004450A (en) Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases.
MX2020008816A (en) Triazine derivatives for treating diseases relating to neurotrophins.
MX2021012491A (en) Anti-proliferative agents for treating pah.
MX2021002188A (en) Novel heterocyclic amine derivative and pharmaceutical composition comprising same.
WO2008087514A3 (en) Hdac inhibitors
MX2020002630A (en) IMIDAZO[1,5-A]PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS.
MX2023000333A (en) Salts and forms of a wee1 inhibitor.
CR20210014A (en) Pyrrolo[1,2-b] pyridazine derivatives
MX2022004215A (en) 5-oxa-2-azaspiro[3.4]octane derivatives as m4 agonists.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20787027

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20787027

Country of ref document: EP

Kind code of ref document: A1